Chesapeake Energy (CHK) Share Price Rose While New Mexico Educational Retirement Board Has Upped Stake; Regeneron Pharmaceuticals (REGN) Position Has Lifted by Healthcor Management Lp

August 12, 2018 - By Catherine Diaz

Chesapeake Energy Corporation (NYSE:CHK) Logo

New Mexico Educational Retirement Board increased its stake in Chesapeake Energy Corp (CHK) by 289.53% based on its latest 2018Q1 regulatory filing with the SEC. New Mexico Educational Retirement Board bought 252,600 shares as the company’s stock rose 33.96% while stock markets declined. The institutional investor held 339,845 shares of the oil & gas production company at the end of 2018Q1, valued at $1.03M, up from 87,245 at the end of the previous reported quarter. New Mexico Educational Retirement Board who had been investing in Chesapeake Energy Corp for a number of months, seems to be bullish on the $4.19 billion market cap company. The stock increased 0.65% or $0.03 during the last trading session, reaching $4.66. About 18.68M shares traded. Chesapeake Energy Corporation (NYSE:CHK) has declined 16.99% since August 12, 2017 and is downtrending. It has underperformed by 29.56% the S&P500. Some Historical CHK News: 17/04/2018 – Fitch Rates Chesapeake Funding II LLC, Series 2018-1; 09/04/2018 – ENVIVA PARTNERS LP – CHESAPEAKE TERMINAL EXPECTED TO RETURN TO FULL OPERATION BY JUNE 30, 2018; 15/05/2018 – Saba Adds Chesapeake Energy, Exits AK Steel, Cuts Cisco: 13F; 28/03/2018 – CHESAPEAKE ENERGY CHK.N CEO SAYS KNOWS NEED TO IMPROVE COMPANY’S BALANCE SHEET, BUT WON’T SELL ASSETS WITHOUT GETTING GOOD VALUE; 28/03/2018 – CHESAPEAKE CEO DOUG LAWLER COMMENTS IN INVESTOR PRESENTATION; 17/04/2018 – Fitch Rates Chesapeake Funding Il LLC, Series 2018-1; 03/04/2018 – Fitch Expects to Rate Chesapeake Funding Il LLC, Series 2018-1; Presale Issued; 23/03/2018 – USDA: Officials View Producer Efforts to Improve Quality of Chesapeake Bay; 07/04/2018 – Federal Register: Special Local Regulation; Chesapeake Bay, between Sandy Point and Kent Island, MD; 02/05/2018 – Chesapeake Energy 1Q Adjusted Ebitda $733M

Healthcor Management Lp increased its stake in Regeneron Pharmaceuticals (REGN) by 92.31% based on its latest 2018Q1 regulatory filing with the SEC. Healthcor Management Lp bought 300,000 shares as the company’s stock declined 9.59% with the market. The hedge fund held 625,000 shares of the health care company at the end of 2018Q1, valued at $215.23 million, up from 325,000 at the end of the previous reported quarter. Healthcor Management Lp who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $39.69 billion market cap company. The stock decreased 0.90% or $3.36 during the last trading session, reaching $368.78. About 564,650 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 35.54% since August 12, 2017 and is downtrending. It has underperformed by 48.11% the S&P500. Some Historical REGN News: 01/05/2018 – Regeneron Pharma: Express Scripts Selected Praluent as Exclusive PCSK9 Inhibitor Therapy on Its National Preferred Formulary as of July 1, 2018; 21/05/2018 – REG-Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma; 30/04/2018 – Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint; 01/05/2018 – Regeneron and Sanofi to Lower Net Price of Praluent (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients; 03/05/2018 – REGENERON PHARMACEUTICALS INC – QTRLY PRALUENT GLOBAL SALES $60 MLN VS $36 MLN; 21/03/2018 – Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH); 03/05/2018 – REGENERON PHARMACEUTICALS INC SEES 2018 CAPITAL EXPENDITURES $420 MLN-$480 MILLION; 03/04/2018 – EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA; 19/03/2018 – EYLEA® (AFLIBERCEPT) INJECTION SHOWS POSITIVE TOPLINE RESULTS; 03/04/2018 – STAT Plus: Sanofi and Regeneron encounter more payer resistance over new eczema drug – this time, in the U.K

More notable recent Chesapeake Energy Corporation (NYSE:CHK) news were published by: Seekingalpha.com which released: “Chesapeake Energy’s Monumental Move” on July 30, 2018, also Seekingalpha.com with their article: “Chesapeake Energy Corp.: Significant Surprise Potential” published on July 16, 2018, 247Wallst.com published: “The 6 Most Shorted NYSE Stocks” on August 10, 2018. More interesting news about Chesapeake Energy Corporation (NYSE:CHK) were released by: Fool.com and their article: “3 Things Chesapeake Energy Corporation’s CEO Wants You to Know About Its Dramatic Transformation” published on August 09, 2018 as well as Benzinga.com‘s news article titled: “Chesapeake’s $2B Asset Sale Dissolves BofA’s Bearish Thesis” with publication date: July 27, 2018.

Investors sentiment increased to 1.28 in Q1 2018. Its up 0.24, from 1.04 in 2017Q4. It is positive, as 69 investors sold CHK shares while 74 reduced holdings. 62 funds opened positions while 121 raised stakes. 516.33 million shares or 5.93% less from 548.86 million shares in 2017Q4 were reported. Financial Architects reported 0% stake. First Interstate National Bank & Trust, Montana-based fund reported 250 shares. First Allied Advisory Inc reported 65,600 shares stake. Meridian Investment Counsel stated it has 0.05% of its portfolio in Chesapeake Energy Corporation (NYSE:CHK). Miracle Mile Advsrs Lc reported 0.01% in Chesapeake Energy Corporation (NYSE:CHK). Veritable LP stated it has 36,113 shares. Verition Fund Management Ltd Liability Co stated it has 57,115 shares. Citigroup Inc reported 0% stake. Barrow Hanley Mewhinney And Strauss Ltd Co reported 10.80M shares or 0.05% of all its holdings. State Of New Jersey Common Pension Fund D has 0.07% invested in Chesapeake Energy Corporation (NYSE:CHK) for 6.00M shares. Moreover, Duncker Streett & has 0% invested in Chesapeake Energy Corporation (NYSE:CHK). Panagora Asset Inc reported 155,971 shares stake. Greylin Invest Mangement holds 0.26% or 393,875 shares in its portfolio. Bluefin Trading Limited Liability Corp accumulated 138,919 shares. Oz Mgmt Limited Partnership holds 0.01% or 499,400 shares.

Among 33 analysts covering Chesapeake Energy Corporation (NYSE:CHK), 7 have Buy rating, 11 Sell and 15 Hold. Therefore 21% are positive. Chesapeake Energy Corporation had 100 analyst reports since July 21, 2015 according to SRatingsIntel. Stifel Nicolaus initiated Chesapeake Energy Corporation (NYSE:CHK) rating on Thursday, March 23. Stifel Nicolaus has “Buy” rating and $10 target. RBC Capital Markets maintained the shares of CHK in report on Tuesday, August 11 with “Sector Perform” rating. SunTrust maintained the shares of CHK in report on Tuesday, January 2 with “Buy” rating. The company was upgraded on Thursday, November 10 by Jefferies. On Friday, February 24 the stock rating was upgraded by UBS to “Neutral”. The stock of Chesapeake Energy Corporation (NYSE:CHK) earned “Underperform” rating by Macquarie Research on Wednesday, June 21. Barclays Capital maintained Chesapeake Energy Corporation (NYSE:CHK) on Wednesday, October 11 with “Underweight” rating. Deutsche Bank maintained Chesapeake Energy Corporation (NYSE:CHK) rating on Wednesday, December 9. Deutsche Bank has “Hold” rating and $6 target. As per Wednesday, December 9, the company rating was initiated by JP Morgan. Bernstein downgraded Chesapeake Energy Corporation (NYSE:CHK) on Monday, March 26 to “Sell” rating.

New Mexico Educational Retirement Board, which manages about $2.63 billion US Long portfolio, decreased its stake in Walt Disney Co/The (NYSE:DIS) by 4,400 shares to 143,920 shares, valued at $14.46 million in 2018Q1, according to the filing. It also reduced its holding in Alphabet Inc Cl A by 300 shares in the quarter, leaving it with 28,381 shares, and cut its stake in Jpmorgan Chase Co (NYSE:JPM).

Investors sentiment decreased to 1.05 in Q1 2018. Its down 0.12, from 1.17 in 2017Q4. It dived, as 70 investors sold REGN shares while 158 reduced holdings. 71 funds opened positions while 169 raised stakes. 69.33 million shares or 0.23% more from 69.17 million shares in 2017Q4 were reported. Raymond James Fincl Svcs Advsrs Inc invested in 3,003 shares or 0.01% of the stock. Retirement Sys Of Alabama accumulated 36,890 shares or 0.06% of the stock. Ima Wealth holds 7,003 shares or 1.07% of its portfolio. Northern Tru Corp owns 916,314 shares. Bb&T accumulated 12,322 shares. Blair William And Il accumulated 1,973 shares or 0% of the stock. Eqis Management owns 0.06% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 3,166 shares. Clearbridge Investments Lc has invested 0.27% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Chevy Chase Tru Incorporated has 99,285 shares. Orbimed Llc accumulated 4.11% or 962,900 shares. Cadence Capital Mgmt Limited holds 0.06% or 2,566 shares in its portfolio. Hudson Bay Mgmt LP has invested 0.07% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Jacobs Levy Equity Management holds 1,178 shares. Paradigm Asset Mgmt Company Ltd Liability Corporation accumulated 300 shares. 1832 Asset Mgmt Lp has invested 0% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Benzinga.com which released: “Regeneron To Make $100M bluebird bio Investment In Cancer Research Collaboration” on August 06, 2018, also Schaeffersresearch.com with their article: “Tinder Lights Match Stock on Fire; Plus, Should Celgene Pull a Tesla?” published on August 08, 2018, Seekingalpha.com published: “Replimune set for $101M IPO” on July 14, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Seekingalpha.com and their article: “Regeneron Pharmaceuticals (REGN) Q2 2018 Results – Earnings Call Transcript” published on August 02, 2018 as well as Seekingalpha.com‘s news article titled: “Key events next week for healthcare investors” with publication date: August 03, 2018.

Since February 9, 2018, it had 0 insider buys, and 8 insider sales for $101.46 million activity. 20,000 shares were sold by SING GEORGE L, worth $5.72M on Wednesday, May 9. STAHL NEIL sold 11,407 shares worth $3.37M. 1,000 shares were sold by GOLDSTEIN JOSEPH L, worth $325,600 on Friday, February 9. Sanofi sold $37.61M worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Friday, June 8.

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 11 have Buy rating, 1 Sell and 21 Hold. Therefore 33% are positive. Regeneron Pharmaceuticals Inc. had 134 analyst reports since July 28, 2015 according to SRatingsIntel. On Thursday, February 8 the stock rating was maintained by Guggenheim with “Buy”. The firm earned “Hold” rating on Thursday, August 3 by J.P. Morgan. The stock has “Hold” rating by Oppenheimer on Thursday, August 3. Leerink Swann maintained the stock with “Outperform” rating in Monday, August 3 report. The firm has “Equal-Weight” rating given on Friday, February 9 by Morgan Stanley. The rating was initiated by Bernstein on Wednesday, June 29 with “Outperform”. Piper Jaffray maintained the shares of REGN in report on Thursday, January 18 with “Buy” rating. The stock has “Buy” rating by Gabelli on Tuesday, March 15. The rating was upgraded by Zacks on Tuesday, August 11 to “Hold”. UBS maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Thursday, September 21 with “Buy” rating.

Healthcor Management Lp, which manages about $3.20 billion and $2.94B US Long portfolio, decreased its stake in Incyte Corp (NASDAQ:INCY) by 1.22M shares to 130,910 shares, valued at $10.91M in 2018Q1, according to the filing. It also reduced its holding in Celgene Corp (NASDAQ:CELG) by 1.04 million shares in the quarter, leaving it with 681,030 shares, and cut its stake in Abbvie Inc (NYSE:ABBV).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts